Analysis of TCGA data of CD40 expression in pancreatic adenocarcinoma, melanoma and RCC demonstrated a strong correlation with Ag presentation molecules, TLRs and T cell function supporting the use of CD40 agonists as an attractive cancer immune therapy for DC activation [415]. This evidence concerns the gene CD40 and renal cell adenocarcinoma.